Mononeuritis secondary to rheumatoid arthritis responds to etanercept

Richter, Constanze

doi:10.1093/rheumatology/39.12.1436

Cited by 13 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Commentary: There are nine case series of treating rheumatoid vasculitis using TNF inhibitors; thus, the evidence level is V and the recommendation level is 1C. Serum TNF‐α levels are elevated in RA patients with rheumatoid vasculitis compared to those without rheumatoid vasculitis, and serum levels of CX3CL1 produced by vascular endothelial cells stimulated by TNF‐α are correlated with rheumatoid vasculitis severity . Therefore, TNF‐α may be closely involved in the pathogenic mechanism of rheumatoid vasculitis, while TNF inhibitors are expected to be sufficiently useful for treating rheumatoid vasculitis. Regarding the usefulness of TNF inhibitors for treating rheumatoid vasculitis, there are only case reports and one case series.…”

Section: Cq26: Are Tumor Necrosis Factor (Tnf) Inhibitors Useful For mentioning

confidence: 99%

Wound, pressure ulcer and burn guidelines – 4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers

Fujimoto

Asai

Asano

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Cq26: Are Tumor Necrosis Factor (Tnf) Inhibitors Useful For mentioning

confidence: 99%

Wound, pressure ulcer and burn guidelines – 4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers

Fujimoto

Asai

Asano

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Mononeuritis multiplex is treated as a vasculitis with high-dose IV methylprednisolone and cyclophosphamide [72]. Whether anti-TNF agents are helpful remains unclear; although there are cases of successful treatment of refractory rheumatoid vasculitis [73,74], there is also increased incidence of anti-TNF agent-induced peripheral neuropathy [75]. As we have observed demyelinating neuropathies caused by these agents, we do not recommend them in cases of already existing neuropathy.…”

Section: Inflammatory Arthritismentioning

confidence: 99%

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

et al. 2016

View full text Add to dashboard Cite

Neurological involvement is relatively common in the majority of systemic autoimmune diseases and may lead to severe morbidity and mortality, if not promptly treated. Treatment options vary greatly, depending on the underlying systemic pathophysiology and the associated neurological symptoms. Selecting the appropriate therapeutic scheme is further complicated by the lack of definite therapeutic guidelines, the necessity to differentiate primary neurological syndromes from those related to the underlying systemic disease, and to sort out adverse neurological manifestations caused by immunosuppressants or the biological agents used to treat the primary disease. Immunotherapy is a sine qua non for treating most, if not all, neurological conditions presenting in the context of systemic autoimmunity. Specific agents include classical immune modulators such as corticosteroids, cyclophosphamide, intravenous immunoglobulin, and plasma exchange, as well as numerous biological therapies, for example antitumor necrosis factor agents and monoclonal antibodies that target various immune pathways such as B cells, cytokines, and co-stimulatory molecules. However, experience regarding the use of these agents in neurological complications of systemic diseases is mainly empirical or based on small uncontrolled studies and case series. The aim of this review is to present the state-of-the-art therapies applied in various neurological manifestations encountered in the context of systemic autoimmune diseases; evaluate all treatment options on the basis of existing guidelines; and compliment these data with our personal experience derived from a large number of patients.

show abstract

“…Comments: There are nine case series studies regarding treatment for rheumatoid vasculitis using TNF inhibitors, and the evidence level is V. In RA patients with rheumatoid vasculitis, the serum TNF‐α level is increased compared with those without rheumatoid vasculitis, and the serum level of CX3CL1 produced by vascular endothelial cells stimulated by TNF‐α is correlated with the severity of rheumatoid vasculitis . Therefore, TNF‐α may be closely involved in the pathogenic mechanism of rheumatoid vasculitis, and TNF inhibitors are expected to be sufficiently useful for the treatment also of rheumatoid vasculitis. Concerning the usefulness of TNF inhibitors for the treatment of rheumatoid vasculitis, there are only case reports and a case series study.…”

Section: Cq20: Are Tumor Necrosis Factor (Tnf) Inhibitors Useful For mentioning

confidence: 99%

The wound/burn guidelines – 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis

Fujimoto

Asano

Ishii

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

The Japanese Dermatological Association prepared guidelines focused on the treatment of skin ulcers associated with connective tissue disease/vasculitis practical in clinical settings of dermatological care. Skin ulcers associated with connective tissue diseases or vasculitis occur on the background of a wide variety of diseases including, typically, systemic sclerosis but also systemic lupus erythematosus (SLE), dermatomyositis, rheumatoid arthritis (RA), various vasculitides and antiphospholipid antibody syndrome (APS). Therefore, in preparing the present guidelines, we considered diagnostic/therapeutic approaches appropriate for each of these disorders to be necessary and developed algorithms and clinical questions for systemic sclerosis, SLE, dermatomyositis, RA, vasculitis and APS.Key words: antiphospholipid antibody syndrome, dermatomyositis, rheumatoid arthritis, systemic lupus erythematosus, vasculitis.Correspondence: Hironobu Ihn, M.D., Ph.D., Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan. Email: ihn-der@kumamoto-u.ac.jp This is the secondary English version of the original Japanese manuscript for The wound/burn guidelines -4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis published in

show abstract

Mononeuritis secondary to rheumatoid arthritis responds to etanercept

Cited by 13 publications

References 3 publications

Wound, pressure ulcer and burn guidelines – 4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers

Wound, pressure ulcer and burn guidelines – 4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

The wound/burn guidelines – 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis

Contact Info

Product

Resources

About